These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15720272)

  • 1. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials.
    Burczynski ME; Oestreicher JL; Cahilly MJ; Mounts DP; Whitley MZ; Speicher LA; Trepicchio WL
    Curr Mol Med; 2005 Feb; 5(1):83-102. PubMed ID: 15720272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of oncology drug response markers using transcription profiling.
    Dracopoli NC
    Curr Mol Med; 2005 Feb; 5(1):103-10. PubMed ID: 15720273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
    O'Donnell PH; Stadler WM
    Clin Cancer Res; 2012 May; 18(10):2809-16. PubMed ID: 22427349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
    Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
    JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping.
    Vizirianakis IS
    Clin Pharmacokinet; 2007; 46(10):807-24. PubMed ID: 17854232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
    Marquart J; Chen EY; Prasad V
    JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expectations, validity, and reality in gene expression profiling.
    Kim K; Zakharkin SO; Allison DB
    J Clin Epidemiol; 2010 Sep; 63(9):950-9. PubMed ID: 20579843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.
    Jürgensmeier JM; Eder JP; Herbst RS
    Clin Cancer Res; 2014 Sep; 20(17):4425-35. PubMed ID: 25183480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy and pharmacogenomic programs.
    Iqbal S; Lenz HJ
    Cancer; 2003 Apr; 97(8 Suppl):2076-82. PubMed ID: 12673699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression-driven diagnostics and pharmacogenomics in cancer.
    Wang Y
    Curr Opin Mol Ther; 2005 Jun; 7(3):246-50. PubMed ID: 15977422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the consistency of large-scale pharmacogenomic studies.
    Rahman R; Dhruba SR; Matlock K; De-Niz C; Ghosh S; Pal R
    Brief Bioinform; 2019 Sep; 20(5):1734-1753. PubMed ID: 31846027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarrays to identify new therapeutic strategies for cancer.
    Sears C; Armstrong SA
    Adv Cancer Res; 2007; 96():51-74. PubMed ID: 17161676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized medicine in oncology: where have we come from and where are we going?
    André F; Ciccolini J; Spano JP; Penault-Llorca F; Mounier N; Freyer G; Blay JY; Milano G
    Pharmacogenomics; 2013 Jun; 14(8):931-9. PubMed ID: 23746187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized medicine and economic evaluation in oncology: all theory and no practice?
    Garattini L; Curto A; Freemantle N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
    Yan L; Beckman R
    Biotechniques; 2005 Oct; 39(10 Suppl):S565-8. PubMed ID: 18957038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics in the age of personalized medicine.
    Dickmann LJ; Ware JA
    Drug Discov Today Technol; 2016; 21-22():11-16. PubMed ID: 27978982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic applications in clinical drug development.
    Dracopoli NC
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S57-60. PubMed ID: 12856151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.